6th Annual IBDHorizons Midwest Symposium

Speakers

• 
  
  
  Anita Afzali, MD, MPH, MHCM Professor of Medicine in the Division of Digestive Diseases, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System
  

  Anita Afzali, MD, MPH, MHCM

  Professor of Medicine in the Division of Digestive Diseases, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System

  Dr. Anita Afzali is a Professor of Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. She is also the Associate Chief Medical Officer of the UC Health System. She received her medical degree and then completed Internal Medicine residency and gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and graduated with a Masters in Public Health from The University of Washington. She then later obtained another Masters In Healthcare Management (MHCM) from Harvard T.H. Chan School of Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty.

  While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics. After Seattle, Dr. Afzali moved to Columbus, OH to be the Medical Director of The OSU IBD Center and the Vice Chair of Clinical Operations of Gastroenterology at The Ohio State University.

  Recently, she has transitioned to the University of Cincinnati where she serves as the Executive Vice Chair of the Department of Internal Medicine. Her research interests include drug study design, investigational drug trials, and clinical outcomes. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Chair of the American College of Gastroenterology (ACG) Educational Affairs Committee and Vice Chair of Publications Committee for the World Gastroenterology Organization (WGO).

• 
  
  
  Brian Feagan, MD, MSc Professor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc
  

  Brian Feagan, MD, MSc

  Professor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc

  Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Inflammatory Bowel Diseases (IBD), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in IBD. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc).

  Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology (ACG), the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation (CCF) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored numerous articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).

• 
  
  
  Feza Remzi, MD Vice President and Colorectal Surgeon at Northwell Health Center for Advanced IBD Care, New York
  

  Feza Remzi, MD

  Vice President and Colorectal Surgeon at Northwell Health Center for Advanced IBD Care, New York

  Dr. Feza Remzi is the Vice President and a colorectal surgeon at the Center for Advanced IBD Care at Northwell Health in New York.

  He is a national and international expert in colorectal surgery, specializing in the surgical management of inflammatory bowel disease (IBD). He performs pelvic pouch surgery, complex abdominopelvic re-operative surgery, and sphincter-saving surgery for rectal cancer, utilizing minimally invasive techniques to manage colorectal conditions.

  Dr. Remzi resides in New York with his wife and son. They enjoy traveling and spending time together as a family.

  Dr. Remzi is an Honorary IBDHorizons Board member.

  @FezaRemziMD

• 
  
  
  Ghassan Wahbeh, MD Director of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine and Director of Clinical Gastroenterology Operations.​
  

  Ghassan Wahbeh, MD

  Director of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine and Director of Clinical Gastroenterology Operations.​

  Ghassan Wahbeh, MD, is the Director of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. He is a Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine and Director of Clinical Gastroenterology Operations. Dr. Wahbeh’s clinical focus is in advanced care for children, adolescents, and young adults with IBD, including advanced therapeutics and perioperative IBD management. He leads the Intestinal Ultrasound (IUS) Program at Seattle Children’s.

  Dr. Wahbeh’s research interests include novel therapeutics for pediatric IBD, advanced disease monitoring towards mucosal healing, clinical standard work in managing severe ulcerative colitis and complicated Crohn’s disease including fistulizing and stricturing phenotypes, and navigating IBD surgical options. He is actively involved in translational IBD research at Seattle Children’s Hospital.

  Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training and fellow physician specialty, and advanced IBD specialty training.

  He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohn’s & Colitis Foundation service award. Dr. Wahbeh enjoys playing soccer, skiing, and paddle-boarding with his wife and kids.

  Dr. Ghassan Wahbeh is a co-founder of IBDHorizons

  @PedsIBD_Wahbeh

• 
  
  
  Kara De Felice, MD Associate Professor of Clinical Medicine; Director of University of Cincinnati Health IBD Center
  

  Kara De Felice, MD

  Associate Professor of Clinical Medicine; Director of University of Cincinnati Health IBD Center

  Dr. De Felice is an Associate Professor of Clinical Medicine and the Director of Inflammatory Bowel Diseases (IBD) at the University of Cincinnati. She is building a multidisciplinary IBD Center with the goal to provide excellent IBD patient care, improve patient outcomes, participate in research, and train the next generation of gastroenterologists. Dr. De Felice loves to travel, play tennis, watch football, have dinner and cocktails parties.

  @KDeFelice_IBD

• 
  
  
  Marla Dubinsky, MD Professor of Pediatrics and Medicine at the Icahn School of Medicine; Co-Director of the IBD Preconception and Pregnancy Planning Clinic at Mount Sinai, New York
  

  Marla Dubinsky, MD

  Professor of Pediatrics and Medicine at the Icahn School of Medicine; Co-Director of the IBD Preconception and Pregnancy Planning Clinic at Mount Sinai, New York

  Marla C. Dubinsky, MD, is a Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. She received her medical degree from Queen’s University, Canada. Dr. Dubinsky completed her pediatric residency at Alberta Children’s Hospital, Calgary, Canada, and her clinical fellowship in gastroenterology and nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She completed her research fellowship in IBD at Cedars-Sinai Medical Center in Los Angeles, CA, where she served as the Director of the Pediatric IBD Center before going to Mount Sinai as the Chief of Pediatric Gastroenterology and Nutrition at the Mount Sinai Kravis Children’s Hospital and Co-Director of the Susan and Leonard Feinstein IBD Clinical Center. Dr. Dubinsky is also the Co-Director of the IBD Preconception and Pregnancy Planning Clinic at Mount Sinai. She is the Co-Founder of Mi-Test Health, and Cornerstones Health which is a non-profit organization dedicated to enhancing and transforming communication between health care providers, patients, and industry partners through creative, comprehensive, and expert-based educational program. She is also the Co-Founder of Trellus Health, a resilience driven connected health solution for chronic conditions.  

  Dr. Dubinsky has been engaged in inflammatory bowel disease (IBD) clinical and translational research for over two decades. Her primary research focuses on developing predictive models and web-based decision support tools that integrate clinical and biomarkers to predict the natural history of IBD and response to therapy. She has a keen interest in personalized medicine in IBD and her research uncovers predictors of rapid disease progression with the goal of preventing complications by altering treatment plans. Dr. Dubinsky is the principal investigator of multiple large longitudinal cohorts including the Road to Prevention Multiplex Family Program at Mount Sinai with over 700 enrolled participants with a goal of using multi-omic data to predict the development of IBD in unaffected family members and co-investigator of the Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn’s Disease (RISK) study and senior author on the manuscript presenting a model to predict the natural history of pediatric Crohn’s disease. Dr. Dubinsky is very committed to women’s reproductive health in IBD and in addition to her research in this field she is the Co-founder of WECARE in IBD, an organization dedicated to the health of women with IBD. She has lectured widely, both nationally and internationally, and has published in more than 260 peer-reviewed journals, including Gastroenterology, Lancet, JAMA, The Journal of Pediatric Gastroenterology and Nutrition, The Journal of Crohn’s and Colitis (JCC360), Inflammatory Bowel Diseases, and the American Journal of Gastroenterology (AJG).

  Dr. Dubinsky was the recipient of the 2022 Sherman Prize recognizing her outstanding achievements in IBD.

• 
  
  
  Miguel Regueiro, MD Professor of Medicine at Cleveland Clinic
  

  Miguel Regueiro, MD

  Professor of Medicine at Cleveland Clinic

  Dr. Regueiro is a Professor of Medicine whose research efforts involve inflammatory bowel disease (IBD) and specifically investigate the natural course of postoperative Crohn’s disease, medications to prevent Crohn’s disease recurrence, novel IBD medications, and phenotypes that correlate with genotypes for IBD. He has also recently developed interests in patient centered care and outcomes with the creation of the specialty medical home. This novel approach to IBD population-based health has led to research with the Health Plan (insurance company) on quality of life, clinical outcomes, and reduction in unplanned care. Management of patients with IBD. As part of a tertiary referral center, complex IBD patients are often referred for second opinion and assistant in treatment plans. Providing multidisciplinary, patient-centered care is a primary interest.

• 
  
  
  Scott D. Lee, MD Associate Professor of Medicine, Director, Clinical Inflammatory Bowel Disease Program at University of Washington Medical Center
  

  Scott D. Lee, MD

  Associate Professor of Medicine, Director, Clinical Inflammatory Bowel Disease Program at University of Washington Medical Center

  Dr. Scott D. Lee is an Associate Professor of Medicine with expertise in inflammatory bowel diseases. Dr. Lee earned his bachelor’s degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center. Currently, his clinical practice is at the Digestive Disease Center at the University of Washington and is dedicated exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long-term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients, and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program. He is a member of the Crohn’s Colitis Foundation of America (CCF), American Gastroenterology Association (AGA), American College of Gastroenterology (ACG), and American Society of Gastrointestinal Endoscopy (ASGE). He is a past chair of Northwest CCF Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.

• 
  
  
  Stephen B. Hanauer, MD Professor of Medicine, Clinical Pharmacology, Chief of the Section of Gastroenterology and Nutrition
  

  Stephen B. Hanauer, MD

  Professor of Medicine, Clinical Pharmacology, Chief of the Section of Gastroenterology and Nutrition

  Stephen B. Hanauer received his bachelor’s degree from the University of Michigan in Ann Arbor, Michigan, and his medical degree, with honors, from the University of Illinois in Chicago, IL. He completed his internship and residency in internal medicine, as well as his fellowship in gastroenterology, at the University of Chicago, where he is currently the Joseph B. Kirsner Professor of Medicine and Clinical Pharmacology, and Chief of the Section of Gastroenterology and Nutrition at the University of Chicago. Is the author or co-author of hundreds of peer-reviewed journal articles, books and book chapters, abstracts, monographs, and editorials. He also designed and maintains a 6000-patient database for the Inflammatory Bowel Disease Registry. He is incoming IBD Section editor for Clinical Gastroenterology and Hepatology, and former Editor-in-Chief of Nature Clinical Practice Gastroenterology and Hepatology, and serves on the editorial boards of numerous other medical journals, including the American Journal of Gastroenterology (AJG), and Inflammatory Bowel Diseases. Is the past chair of the Immunology, Microbiology, and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA). He is also a recipient of the AGA’s Fiterman Award for Clinical Research, and the AGA’s Janssen Award for Clinical Excellence. Additionally, he has been named one of America’s Top Doctors by Castle Connolly Medical Ltd. Has previously served as a member and Chair of the Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee. He currently serves as Chair of the International Organization for Inflammatory Bowel Disease, Secretary-Elect of the American College of Gastroenterology (ACG), and a member of the GI Specialty Board of Internal Medicine.